-+ 0.00%
-+ 0.00%
-+ 0.00%

Perspective Therapeutics Announces 2026 Strategic Priorities With VMT-α-NET Progress, Planned Conference Submissions, Regulatory Engagement, And Mid-To-Late 2026 Updates Across Clinical Pipeline

Benzinga·01/12/2026 12:10:09
Listen to the news
  • Continued strong patient recruitment in neuroendocrine tumors for lead program VMT-α-NET sets the stage for submissions of robust clinical data package for presentation to more medical conferences in 2026, as well as regulatory engagement
  • VMT-α-NET continues to be well-tolerated and shows durable disease control and deepening of tumor response with longer follow-up as reported at ASCO-GI 2026
  • Clinical updates expected in mid to late 2026 for VMT01 targeting melanoma and PSV359 targeting FAP across multiple solid tumors, as well as potential additions to the clinical pipeline to be guided by first-in-human images
  • Company to present updates at 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 2:15 p.m. PT